HRT patches tackle prostate cancer

Key points
- Patches normally used by women to relieve menopausal symptoms could help men with prostate cancer as well.
- Doctors know that giving the female hormone oestrogen can also shut off testosterone production, but trials using oestrogen tablets have been abandoned due to an increased risk of blood clotting.
- Mr Paul Abel, one of the consultants leading the trial, said: "We're delighted with the results of this preliminary study.
- A study carried out by researchers at Hammersmith Hospital, and Imperial College, in London, found that the patches offered a kinder alternative than many of the radical hormone therapies currently used.
Patches normally used by women to relieve menopausal symptoms could help men with prostate cancer as well.
A study carried out by researchers at Hammersmith Hospital, and Imperial College, in London, found that the patches offered a kinder alternative than many of the radical hormone therapies currently used.
The prostate is a gland found near the bladder on men, and tumours there are some of the most common in men.
The idea behind hormone therapy of prostate tumours is to cut the supply of the male hormone testosterone, which can encourage cancer cell growth.
Currently, many men are given drugs which reduce testosterone - some even have their testicles removed to achieve the same effect.
However, the side-effects of these therapies can be severe - many men suffer "menopausal" symptoms such as hot flushes, and osteoporosis, and other distressing effects such as impotence and breast growth.
Oestrogen alternative
"The beauty of patch therapy is that is not only leads to disease regression, it does so with far fewer side-effects "
Mr Paul Abel, Hammersmith Hospital
Doctors know that giving the female hormone oestrogen can also shut off testosterone production, but trials using oestrogen tablets have been abandoned due to an increased risk of blood clotting.
The patches, however, have been far more successful.
The researchers found that 20 patients with advanced prostate cancer enjoyed a far better quality of life using patches.
In addition, their disease "regressed", and bone density improved.
There were no reports of dangerous blood clotting.
Delight
Mr Paul Abel, one of the consultants leading the trial, said: "We're delighted with the results of this preliminary study.
"It holds real promise for prostate cancer sufferers giving an efficient, easy and cost-effective alternative to the currently available therapies, which can be painful, time-consuming and produce unwelcome side-effects.
"The beauty of patch therapy is that is not only leads to disease regression, it does so with far fewer side-effects.
"It is also flexible in that it can be removed at any time if necessary, for example should side-effects develop."
He said that an additional advantage was cost - the patches are far cheaper than current therapies, and would potentially save the NHS millions each year.
Content provided by ArmMed Media
Revision date: 12 December 2007
Last revised by Amalia K. Gagarina, M.S., R.D.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsHow does prostate cancer form?
Prostate cancer affects more than 23,000 men this year in the USA however the individual genes that initiate prostate cancer formation are poorly understood. Finding an enzyme that regulates this process could provide…
19 December 2014
NewsCommon prostate cancer treatment associated with decreased survival in older men
A common prostate cancer therapy should not be used in men whose cancer has not spread beyond the prostate, according to a new study led by researchers at Henry Ford Hospital. The findings are particularly important for…
5 December 2014
NewsTestosterone promotes prostate cancer in rats
A researcher who found that testosterone raised the risk of prostate tumors and exacerbated the effects of carcinogenic chemical exposure in rats is urging caution in prescribing testosterone therapy to men who have not…
8 October 2014





